Hepatitis C Management in Special Populations
Summary
- Women of reproductive age who have been diagnosed with HCV infection should be counseled about the benefit of antiviral treatment before pregnancy
- Treatment with DAAs during pregnancy is not recommended as only limited safety and efficacy data are available (Management Guidelines)[AASLD-IDSA HCV; Chappell 2020]
- Ribavirin is contraindicated in pregnancy due to its known teratogenic effects
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content